Literature DB >> 11600549

Prevalence, characteristics and diabetes risk associated with transient maternally acquired islet antibodies and persistent islet antibodies in offspring of parents with type 1 diabetes.

H E Naserke1, E Bonifacio, A G Ziegler.   

Abstract

Accurate assessment of type 1 diabetes risk in young children requires discrimination between antibodies that are produced by the child and antibodies acquired through the placenta from an islet antibody-positive mother. We studied 682 offspring from mothers with type 1 diabetes and 329 offspring from fathers with type 1 diabetes and nondiabetic mothers for insulin (auto)antibodies, glutamic acid decarboxylase antibodies, and tyrosine phosphatase IA-2 antibodies before age 1 yr and again at age 2 yr to ascertain transience or persistence. Antibodies were detected at age 9 months in 5 (1.5%) offspring from fathers with type 1 diabetes; all were insulin (auto)antibodies only, all persisted and developed multiple antibodies, and 1 developed type 1 diabetes. In contrast, 31 (4.5%) offspring from mothers with type 1 diabetes had antibodies at 9 months; 12 (1.8%) persisted at age 2 yr, and 19 (2.8%) did not persist, suggestive of transient residual maternal antibodies. Multiple antibodies at 9 months were usually persistent (3 of 4 offspring), as were single insulin (auto)antibodies in offspring from mothers with type 1 diabetes (8 of 13 offspring), whereas persistent glutamic acid decarboxylase antibodies (1 of 12) and tyrosine phosphatase IA-2 antibodies (0 of 2) were rare. Offspring with persistent antibodies at age 9 months had a high type 1 diabetes risk (100% by age 5 yr for those with multiple antibodies and 27% for single antibodies at 9 months), whereas offspring with transient antibodies had 0% type 1 diabetes risk (P < 0.01). Transience was associated with very high antibody levels at birth. For insulin (auto)antibodies, the measurement of subclass was also informative. Residual maternal antibody was indicated by similar insulin (auto)antibodies subclasses at 9 months and at birth, whereas different subclasses were indicative of nonmaternal antibody. Moreover, the presence of IgG1-insulin (auto)antibodies was associated with antibody persistence and type 1 diabetes risk. These strategies are helpful in discriminating high and low risk antibodies before age 1 yr and should be important for prognosis and reducing unnecessary parent anxiety.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11600549     DOI: 10.1210/jcem.86.10.7931

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  Longitudinal epitope analysis of insulin-binding antibodies in type 1 diabetes.

Authors:  T R Hall; J W Thomas; C J Padoa; C Torn; M Landin-Olsson; E Ortqvist; C S Hampe
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

2.  Evidence for immunological priming and increased frequency of CD4+ CD25+ cord blood T cells in children born to mothers with type 1 diabetes.

Authors:  B C Holm; J Svensson; C Akesson; J Arvastsson; J Ljungberg; K Lynch; S-A Ivarsson; A Lernmark; C M Cilio
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

Review 3.  Autoimmunity and familial risk of type 1 diabetes.

Authors:  Anu-Maaria Hämäläinen; Mikael Knip
Journal:  Curr Diab Rep       Date:  2002-08       Impact factor: 4.810

4.  The postnatal maternal environment influences diabetes development in nonobese diabetic mice.

Authors:  L R Washburn; H Dang; J Tian; D L Kaufman
Journal:  J Autoimmun       Date:  2007-01-04       Impact factor: 7.094

5.  Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations.

Authors:  G Shankar; S Arkin; L Cocea; V Devanarayan; S Kirshner; A Kromminga; V Quarmby; S Richards; C K Schneider; M Subramanyam; S Swanson; D Verthelyi; S Yim
Journal:  AAPS J       Date:  2014-04-24       Impact factor: 4.009

Review 6.  Predicting type 1 diabetes.

Authors:  Peter Achenbach; Ezio Bonifacio; Anette-G Ziegler
Journal:  Curr Diab Rep       Date:  2005-04       Impact factor: 4.810

Review 7.  Prediction and pathogenesis in type 1 diabetes.

Authors:  Anette-G Ziegler; Gerald T Nepom
Journal:  Immunity       Date:  2010-04-23       Impact factor: 31.745

8.  IDDM2/insulin VNTR modifies risk conferred by IDDM1/HLA for development of Type 1 diabetes and associated autoimmunity.

Authors:  M Walter; E Albert; M Conrad; E Keller; M Hummel; K Ferber; B J Barratt; J A Todd; A-G Ziegler; E Bonifacio
Journal:  Diabetologia       Date:  2003-05-16       Impact factor: 10.122

Review 9.  Islet Autoantibodies.

Authors:  Vito Lampasona; Daniela Liberati
Journal:  Curr Diab Rep       Date:  2016-06       Impact factor: 4.810

10.  Reversion of β-Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study.

Authors:  Kendra Vehik; Kristian F Lynch; Desmond A Schatz; Beena Akolkar; William Hagopian; Marian Rewers; Jin-Xiong She; Olli Simell; Jorma Toppari; Anette-G Ziegler; Åke Lernmark; Ezio Bonifacio; Jeffrey P Krischer
Journal:  Diabetes Care       Date:  2016-06-16       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.